Regulation of peroxisome proliferator-activated receptor-γ by angiotensin II via transforming growth factor-β1-activated p38 mitogen-activated protein kinase in aortic smooth muscle cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 2, 2012, Pages 397-405

  Subramanian, Venkateswaran ^a   Golledge, Jonathan ^b   Heywood, Elizabeth B ^a   Bruemmer, Dennis ^a   Daugherty, Alan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b JAMES COOK UNIVERSITY   (Australia)

Author keywords

angiotensin II; atherosclerosis; signal transduction; smooth muscle cells; vascular biology

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; HISTONE DEACETYLASE 3; LOSARTAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUTRALIZING ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; SMAD2 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; AORTA; ARTICLE; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; SMOOTH MUSCLE FIBER;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA; CELLS, CULTURED; ENZYME INHIBITORS; HISTONE DEACETYLASES; IMIDAZOLES; LOSARTAN; MALE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PPAR GAMMA; PYRIDINES; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84856219916     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.239897     Document Type: Article

References (41)

1. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferatoractivated receptors, orphans with ligands and functions. Curr Opin Lipidol. 1997;8:159-166.
2. Olefsky JM. Treatment of insulin resistance with peroxisome proliferatoractivated receptor γ agonists. J Clin Invest. 2000;106:467-472.
3. Hsueh WA, Bruemmer D. Peroxisome proliferator-activated receptor-γ: implications for cardiovascular disease. Hypertension. 2004;43:297-305.
4. Levi Z, Shaish A, Yacov N, Levkovitz H, Trestman S, Gerber Y, Cohen H, Dvir A, Rhachmani R, Ravid M, Harats D. Rosiglitazone (PPARδ-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model. Diabetes Obes Metab. 2003;5:45-50.
5. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000; 106:523-531.
6. Subramanian V, Golledge J, Ijaz T, Bruemmer D, Daugherty A. Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPARδ . Circ Res. 2010;107: 953-958.
7. Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K, Kanaide H, Takeshita A. Peroxisome proliferator-activated receptor γ activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 2000;102:1834-1839.
8. Xi XP, Graf K, Goetze S, Fleck E, Hsueh WA, Law RE. Central role of the MAPK pathway in ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999; 19:73-82.
9. Alexis JD, Wang N, Che W, Lerner-Marmarosh N, Sahni A, Korshunov VA, Zou Y, Ding B, Yan C, Berk BC, Abe J. Bcr kinase activation by angiotensin II inhibits peroxisome-proliferator-activated receptor γ transcriptional activity in vascular smooth muscle cells. Circ Res. 2009;104: 69-78.
10. Du BH, Fu CZ, Kent KC, Bush H, Schulick AH, Kreiger K, Collins T, McCaffrey TA. Elevated Egr-1 in human atherosclerotic cells transcriptionally represses the transforming growth factor-α type II receptor. J Biol Chem. 2000;275:39039-39047.
11. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor-α 1 expression determines growth response to angiotensin II. J Clin Invest. 1992;90: 456-461.
12. Massague J, Wotton D. Transcriptional control by the TGF-β/Smad signaling system. EMBO J. 2000;19:1745-1754.
13. Yu L, Hebert MC, Zhang YE. TGF-β receptor-activated p38 MAP kinase mediates Smad-independent TGF-β responses. EMBO J. 2002;21: 3749-3759.
14. Fu M, Zhang J, Zhu X, Myles DE, Willson TM, Liu X, Chen YE. Peroxisome proliferator-activated receptor γ inhibits transforming growth factor β-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3. J Biol Chem. 2001;276:45888-45894.
15. Fu M, Zhang J, Lin Y, Zhu X, Zhao L, Ahmad M, Ehrengruber MU, Chen YE. Early stimulation and late inhibition of peroxisome proliferator-activated receptor γ (PPARδ ) gene expression by transforming growth factor βin human aortic smooth muscle cells: role of early growth-response factor-1 (Egr-1), activator protein 1 (AP1) and Smads. Biochem J. 2003;370: 1019-1025.
16. Ray JL, Leach R, Herbert JM, Benson M. Isolation of vascular smooth muscle cells from a single murine aorta. Methods Cell Sci. 2001;23: 185-188.
17. Daugherty A, Rateri DL, Lu H, Inagami T, Cassis LA. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation. 2004;110: 3849-3857.
18. Ogawa D, Nomiyama T, Nakamachi T, Heywood EB, Stone JF, Berger JP, Law RE, Bruemmer D. Activation of peroxisome proliferator-activated receptor γ suppresses telomerase activity in vascular smooth muscle cells. Circ Res. 2006;98:e50-e59.
19. Siegert A, Ritz E, Orth S, Wagner J. Differential regulation of transforming growth factor receptors by angiotensin II and transforming growth factor-α 1 in vascular smooth muscle. J Mol Med. 1999;77: 437-445.
20. Syrovets T, Schule A, Jendrach M, Buchele B, Simmet T. Ciglitazone inhibits plasmin-induced proinflammatory monocyte activation via modulation of p38 MAP kinase activity. Thromb Haemost. 2002;88:274-281.
21. Benkirane K, Amiri F, Diep QN, El Mabrouk M, Schiffrin EL. PPAR-α inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol. 2006;290:H390-H397.
22. Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells: metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem. 2001;276: 7957-7962.
23. Fajas L, Egler V, Reiter R, Hansen J, Kristiansen K, Debril MB, Miard S, Auwerx J. The retinoblastoma-histone deacetylase 3 complex inhibits PPARδ and adipocyte differentiation. Dev Cell. 2002;3:903-910.
24. Xu X, Ha CH, Wong C, Wang W, Hausser A, Pfizenmaier K, Olson EN, McKinsey TA, Jin ZG. Angiotensin II stimulates protein kinase D-dependent histone deacetylase 5 phosphorylation and nuclear export leading to vascular smooth muscle cell hypertrophy. Arterioscler Thromb Vasc Biol. 2007;27:2355-2362.
25. Zhuo J, Moeller I, Jenkins T, Chai SY, Allen AM, Ohishi M, Mendelsohn FA. Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors. J Hypertens. 1998;16:2027-2037.
26. Allen AM, Zhuo J, Mendelsohn FA. Localization and function of angiotensin AT1 receptors. Am J Hypertens. 2000;13:31S-38S.
27. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor- γactivity. Circulation. 2004;109:2054-2057.
28. Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor γ . Cardiovasc Res. 2006;72:184-190.
29. Schupp M, Lee LD, Frost N, Umbreen S, Schmidt B, Unger T, Kintscher U. Regulation of peroxisome proliferator-activated receptor γ activity by losartan metabolites. Hypertension. 2006;47:586-589.
30. Rosenkranz S. TGF-β1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63:423-432.
31. Epstein AM, Throckmorton D, Brophy CM. Mitogen-activated protein kinase activation: an alternate signaling pathway for sustained vascular smooth muscle contraction. J Vasc Surg. 1997;26:327-332.
32. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 2000;101: 1653-1659.
33. Won SM, Park YH, Kim HJ, Park KM, Lee WJ. Catechins inhibit angiotensin II-induced vascular smooth muscle cell proliferation via mitogen-activated protein kinase pathway. Exp Mol Med. 2006;38: 525-534.
34. Lee HM, Lee CK, Lee SH, Roh HY, Bae YM, Lee KY, Lim J, Park PJ, Park TK, Lee YL, Won KJ, Kim B. p38 mitogen-activated protein kinase contributes to angiotensin II-stimulated migration of rat aortic smooth muscle cells. J Pharmacol Sci. 2007;105:74-81.
35. Long X, Miano JM. TGFβ1 utilizes distinct pathways for the transcriptional activation of microRNA 143/145 in human coronary artery smooth muscle cells. J Biol Chem. 2011;286:30119-30129.
36. Knutson SK, Chyla BJ, Amann JM, Bhaskara S, Huppert SS, Hiebert SW. Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J. 2008;27:1017-1028.
37. Song R, Van Buren T, Yosypiv IV. Histone deacetylases are critical regulators of the renin-angiotensin system during ureteric bud branching morphogenesis. Pediatr Res. 2010;67:573-578.
38. Vinh A, Gaspari TA, Liu HB, Dousha LF, Widdop RE, Dear AE. A novel histone deacetylase inhibitor reduces abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. J Vasc Res. 2008;45:143-152.
39. Kee HJ, Sohn IS, Nam KI, Park JE, Qian YR, Yin Z, Ahn Y, Jeong MH, Bang YJ, Kim N, Kim JK, Kim KK, Epstein JA, Kook H. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation. 2006;113:51-59.
40. Javelaud D, Mauviel A. Mammalian transforming growth factor-α s: Smad signaling and physio-pathological roles. Int J Biochem Cell Biol. 2004;36:1161-1165.
41. Seay U, Sedding D, Krick S, Hecker M, Seeger W, Eickelberg O. Transforming growth factor-β-dependent growth inhibition in primary vascular smooth muscle cells is p38-dependent. J Pharmacol Exp Ther. 2005;315:1005-1012.